Epoprostenol
Epoprostenol, Flolan, Veletri (epoprostenol) is a small molecule pharmaceutical. Epoprostenol was first approved as Flolan on 1995-09-20. It is used to treat arteriosclerosis, peripheral vascular diseases, pulmonary hypertension, purpura, and respiratory distress syndrome amongst others in the USA. The pharmaceutical is active against prostaglandin E2 receptor EP1 subtype. In addition, it is known to target prostacyclin receptor and prostaglandin E2 receptor EP4 subtype.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Epoprostenol, Flolan, Veletri
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| diluent flolan | New Drug Application | 2023-10-26 |
| epoprostenol | ANDA | 2025-04-23 |
| flolan | New Drug Application | 2016-06-22 |
| veletri | New Drug Application | 2022-11-28 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J1325 | Injection, epoprostenol, 0.5 mg |
| K0455 | Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol) |
| S0155 | Sterile dilutant for epoprostenol, 50 ml |
| S9347 | Home infusion therapy, uninterrupted, long-term, controlled rate intravenous or subcutaneous infusion therapy (e.g., epoprostenol); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
Clinical
Clinical Trials
202 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 11 | 11 | 16 | 14 | 55 |
| Pulmonary arterial hypertension | D000081029 | — | — | 2 | 10 | 9 | 12 | 13 | 46 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 6 | 7 | 9 | 13 | 37 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | 7 | 9 | 8 | 6 | 31 |
| Depression | D003863 | — | F33.9 | — | — | — | 1 | 14 | 15 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | 8 | 9 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 3 | 1 | 3 | 7 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | 2 | 3 | 6 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 1 | 2 | 2 | 1 | 6 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | 1 | 5 | 6 |
Show 22 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 1 | — | 3 | 4 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 3 | — | — | 4 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | 1 | 3 | — | — | 4 |
| Respiratory tract diseases | D012140 | — | — | — | — | 3 | — | — | 3 |
| Connective tissue diseases | D003240 | EFO_1001986 | M35 | — | — | 3 | — | — | 3 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 2 | 1 | — | 1 | 3 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 1 | — | 1 | 2 |
| Nephrosclerosis | D009400 | EFO_1000041 | I12 | — | 2 | 1 | — | — | 2 |
| Weight loss | D015431 | — | — | — | — | 2 | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | 1 | 2 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 1 | — | — | 5 | 6 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 2 | — | — | 2 | 4 |
| Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | 1 | 2 |
| Reperfusion injury | D015427 | — | — | 1 | 2 | — | — | — | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 2 | — | — | — | 2 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 2 | — | — | — | 2 |
| Obstructive lung diseases | D008173 | — | — | — | 1 | — | — | 1 | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | — | — | — | 2 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 2 | — | — | — | 2 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 4 | 5 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | 1 | 2 |
| Headache | D006261 | — | R51 | 1 | — | — | — | 1 | 2 |
| Traumatic brain injuries | D000070642 | — | S06 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pharmacogenomic testing | D000071185 | — | — | — | — | — | — | 9 | 9 |
| Acute pain | D059787 | — | R52 | — | — | — | — | 6 | 6 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 4 | 4 |
| Chronic pain | D059350 | — | — | — | — | — | — | 4 | 4 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 4 | 4 |
| Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 3 | 3 |
| Polypharmacy | D019338 | — | — | — | — | — | — | 3 | 3 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 3 | 3 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Respiratory distress syndrome | D012128 | EFO_1000637 | J80 | — | — | — | — | 2 | 2 |
Show 56 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Epoprostenol |
| INN | epoprostenol |
| Description | Prostaglandin I2 is a prostaglandins I. It has a role as a mouse metabolite. It is a conjugate acid of a prostaglandin I2(1-). |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21 |
Identifiers
| PDB | — |
| CAS-ID | 35121-78-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1139 |
| ChEBI ID | 15552 |
| PubChem CID | 5282411 |
| DrugBank | DB01240 |
| UNII ID | DCR9Z582X0 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGER1
PTGER1
Organism
Homo sapiens
Gene name
PTGER1
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin E2 receptor EP1 subtype
Protein synonyms
PGE receptor, EP1 subtype, PGE2 receptor EP1 subtype, prostaglandin E receptor 1 (subtype EP1), 42kD, prostaglandin E receptor 1 (subtype EP1), 42kDa, prostaglandin E receptor 1, subtype EP1, Prostanoid EP1 receptor
Uniprot ID
Mouse ortholog
Ptger1 (19216)
prostaglandin E2 receptor EP1 subtype (P35375)
Alternate
PTGIR
PTGIR
PTGER4
PTGER4
Organism
Homo sapiens
Gene name
PTGIR
Gene synonyms
PRIPR
NCBI Gene ID
Protein name
prostacyclin receptor
Protein synonyms
PGI receptor, PGI2 receptor, prostaglandin I2 (prostacyclin) receptor (IP), Prostaglandin I2 receptor, Prostanoid IP receptor
Uniprot ID
Mouse ortholog
Ptgir (19222)
prostacyclin receptor (Q52KE5)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43,058 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
16,690 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use